Hearing Loss Pipeline

DelveInsight’s, “Hearing Loss - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Hearing Loss pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Hearing Loss: Understanding

Hearing Loss: Overview

Hearing loss refers to a partial or total inability to hear, which can be present at birth or develop later in life. It can affect one or both ears and is categorized into three main types: conductive hearing loss, caused by issues in the outer or middle ear; sensorineural hearing loss, stemming from damage to the inner ear or auditory nerve; and mixed hearing loss, which involves both conductive and sensorineural components. Hearing loss can manifest through various signs and symptoms, often developing gradually and becoming noticeable over time. Common indicators include difficulty hearing conversations, especially in noisy environments, frequently asking others to repeat themselves, and needing to increase the volume on devices like televisions or radios compared to others. Individuals may also experience muffled sounds, misunderstandings during conversations, and fatigue from concentrating on listening.

Hearing loss can be classified into four primary types: Conductive Hearing Loss, Sensorineural Hearing Loss, Mixed Hearing Loss, and Central Auditory Processing Disorder. Conductive hearing loss occurs due to issues in the outer or middle ear, preventing sound from reaching the inner ear. It is often treatable through medical or surgical interventions. Sensorineural hearing loss, the most common type, results from damage to the inner ear or auditory nerve. This type is usually permanent and often managed with hearing aids. Mixed hearing loss is a combination of both conductive and sensorineural components, requiring a tailored approach to treatment. Central Auditory Processing Disorder, on the other hand, affects the brain's ability to process auditory information, meaning individuals can hear sounds but struggle to understand them. Each type of hearing loss presents differently and requires specific approaches for diagnosis and treatment.

Diagnosing hearing loss involves a comprehensive evaluation process that begins with a physical examination by a healthcare provider. Using an otoscope, the provider inspects the ear for potential issues such as earwax buildup, infections, or structural abnormalities. Various screening tests may follow, including the whisper test and tuning fork tests, which help determine the type and severity of hearing loss. If needed, patients are referred to specialists like audiologists for more detailed assessments using audiometers and bone oscillators to measure hearing sensitivity across different frequencies and volumes.

Hearing loss treatment depends on the type and severity of the condition, with various options available to address different cases. Hearing assist devices, such as hearing aids and cochlear implants, can help amplify sound for those with sensorineural hearing loss. Hearing rehabilitation, including auditory training and speech therapy, supports individuals in adapting to their hearing challenges. Listening devices, such as FM systems and amplified telephones, enhance sound clarity in specific environments. Medications may also play a role; for example, antibiotics can treat hearing loss caused by ear infections, while corticosteroids help reduce inflammation in cochlear hair cells after exposure to loud noise.

"Hearing Loss- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hearing Loss pipeline landscape is provided which includes the disease overview and Hearing Loss treatment guidelines. The assessment part of the report embraces, in depth Hearing Loss commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hearing Loss collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hearing Loss R&D. The therapies under development are focused on novel approaches to treat/improve Hearing Loss.

 

Hearing Loss Emerging Drugs Chapters

This segment of the Hearing Loss report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Hearing Loss Emerging Drugs

• SENS-401: Sensorion

SENS-401 (Arazasetron), Sensorion’s clinical stage drug candidate, is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment. Sensorion currently develops SENS-401 in a Phase 2 clinical trial for the prevention of Cisplatin-Induced Ototoxicity and has completed a Phase 2a study to prevent residual hearing loss in patients scheduled for cochlear implantation. SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the US for the prevention of platinum-induced ototoxicity in pediatric population. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of Hearing Loss.

 

• ACOU-085: Acousia Therapeutics

ACOU085 is a first-in-class, small-molecule, etiology-agnostic otoprotective drug candidate delivered using standard, transtympanic administration of a proprietary, slow-release gel formulation. Ototoxic hearing loss is a typical, severe, and permanent side effect of cisplatin treatment and is a consequence of irreversible damage to the sensory cells in the inner ear, the so-called outer hair cells (OHCs). ACOU085 modulates a biologically validated target, the KCNQ4-encoded Kv7.4 potassium channel of the OHCs, and has demonstrated significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity in preclinical models. Currently, the drug is in Phase II stage of its clinical trial for the treatment of hearing loss.

 

• NS101: Neuracle Science

NS101 is a monoclonal antibody developed by Neuracle Science Co., Ltd., targeting TAFA5, a protein associated with neurodegenerative diseases such as sensorineural hearing loss and Alzheimer's disease. By modulating TAFA5 activity, NS101 aims to restore neural function and mitigate disease progression. Currently, NS101 is undergoing Phase I/II clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in both healthy volunteers and patients with sudden sensorineural hearing loss.

Further product details are provided in the report……..

 

Hearing Loss: Therapeutic Assessment

This segment of the report provides insights about the different Hearing Loss drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Hearing Loss
• There are approx. 30+ key companies which are developing the therapies for Hearing Loss. The companies which have their Hearing Loss drug candidates in the most advanced stage, i.e. Phase II/III include, Sensorion.

 

Phases

DelveInsight’s report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Hearing Loss: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Hearing Loss therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hearing Loss drugs.

 

Hearing Loss Report Insights

• Hearing Loss Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Hearing Loss Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hearing Loss drugs?
• How many Hearing Loss drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hearing Loss?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hearing Loss therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hearing Loss and their status?
• What are the key designations that have been granted to the emerging drugs?